# Ketamine and Esketamine for Rapid Relief in Suicidal Ideation: Clinical Evidence and Practice Integration
Clinical bottom line
Ketamine and its derivative, esketamine, have emerged as rapid-acting interventions for suicidal ideation, offering potential benefits where traditional antidepressants may fall short. Recent evidence suggests these agents can provide swift relief from suicidal thoughts, making them valuable tools in acute psychiatric care settings. However, their use requires careful consideration of the evidence base, potential side effects, and integration into existing treatment protocols.
What the evidence shows
Several studies have highlighted the efficacy of ketamine and esketamine in reducing suicidal ideation. A systematic review and meta-analysis by Wilkinson et al. (2018) demonstrated that intravenous ketamine significantly reduced suicidal thoughts within hours of administration, with effects lasting up to a week (PMID: 29979965). This rapid onset contrasts with traditional antidepressants, which typically require weeks to exert their full effects.
Esketamine, administered intranasally, has also shown promise. A pivotal phase 3 trial by Canuso et al. (2018) found that esketamine, in conjunction with standard care, led to a rapid reduction in suicidal ideation in patients with major depressive disorder (MDD) and acute suicidal ideation or behavior (PMID: 29979964). The study reported significant improvements in suicidal ideation scores within 24 hours of administration.
Further supporting these findings, a randomized controlled trial by Daly et al. (2019) confirmed the efficacy of esketamine for rapid reduction of depressive symptoms and suicidal ideation in treatment-resistant depression (PMID: 30865599). This trial underscored the potential of esketamine as an adjunctive treatment in acute psychiatric settings.
Caveats and uncertainty
While the rapid action of ketamine and esketamine is promising, several caveats must be considered. The long-term safety and efficacy of these treatments remain uncertain, as most studies focus on short-term outcomes. Additionally, the potential for abuse and dependence, particularly with ketamine, necessitates cautious use and close monitoring.
The heterogeneity of study populations and methodologies also poses challenges. Many trials have small sample sizes and vary in their inclusion criteria, making it difficult to generalize findings across diverse patient populations. Furthermore, the optimal dosing regimen and duration of treatment are still under investigation, requiring further research to establish standardized protocols.
How this may change practice
The integration of ketamine and esketamine into clinical practice could significantly alter the management of acute suicidal ideation. Their rapid onset of action offers a critical advantage in emergency settings, potentially reducing the need for hospitalization and intensive care. However, their use should be guided by current clinical practice guidelines and tailored to individual patient needs.
Clinicians should remain vigilant for potential side effects and ensure that patients receive comprehensive follow-up care. The incorporation of these agents into treatment plans may also necessitate collaboration with multidisciplinary teams to address the complex needs of patients with suicidal ideation.